Showing results (41-50 of 119) with videos related to
Sort By:
Pageof 12
Urologic Oncology|November 2, 2020
Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomyNicole Prabhu, Navina Kapur, William Catalona, et al.The Oncologist|May 21, 2021
A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline MutationKelsey T Danley, Karen Schmitz, Ritu Ghai, et al.JAMA Dermatology|February 7, 2014
High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomasJoan Guitart, Janyana Deonizio, Tara Bloom, et al.Cancer|March 29, 2006
Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR projectSteven M Belknap, Timothy M Kuzel, Paul R Yarnold, et al.Leukemia & Lymphoma|October 19, 2007
Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497Timothy M Kuzel, Shuli Li, John Eklund, et al.The Journal of Investigative Dermatology|April 29, 2006
The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathwayChristiane Querfeld, Mujahid A Rizvi, Timothy M Kuzel, et al.Oncotarget|August 13, 2016
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemiaLei Qin, Donye Dominguez, Siqi Chen, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 15, 2015
Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor CellsCong Ye, Zhe Geng, Donye Dominguez, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 31, 2018
Type 2 Innate Lymphoid Cells Impede IL-33-Mediated Tumor SuppressionAlan Long, Donye Dominguez, Lei Qin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2005
In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesnaGerald A Soff, Hao Wang, Deborah L Cundiff, et al.Pageof 12